Kedrion Biopharma
Paolo Morabito is an experienced professional in pharmacovigilance and medical management, currently serving as the Pharmacovigilance Safety Director and Deputy EU/UK QPPV at Kedrion Biopharma from March 2024 to June 2025. Previously, Paolo held various roles at MENARINI Group from March 2017 to April 2021, including responsibilities in signal detection and medical assessment. Prior experience includes working as an Area Specialist/Medical Writer at Merck & Co. and as a Medical Science Manager at Bristol-Myers Squibb, focusing on immunotherapy in oncology. Paolo began his career as a Medico di Continuità Assistenziale at ASP Reggio Calabria in 2015. Paolo holds a degree in Medicine and Surgery from the University of Messina and an MBA in Email Marketing Management from E-Business Academy.
This person is not in any teams
This person is not in any offices
Kedrion Biopharma
19 followers
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. Kedrion distributes its products in over 100 countries around the world. We have plants in Italy, Hungary, UK and North America, and plasma collection centers in the US and in the Czech Republic. With these figures we are the world’s 5th top player in the field of plasma-derived products. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.